Last €36.50 EUR
Change Today -0.13 / -0.35%
Volume 989.7K
GRF On Other Exchanges
As of 11:38 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

grifols sa (GRF) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/10/14 - €42.53
52 Week Low
10/16/14 - €27.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GRIFOLS SA (GRF)

Related News

No related news articles were found.

grifols sa (GRF) Related Businessweek News

No Related Businessweek News Found

grifols sa (GRF) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals, including parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

12,615 Employees
Last Reported Date: 04/4/14
Founded in 1940

grifols sa (GRF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa (GRF) Key Developments

Grifols Wins EUR 198,000 Pharmaceuticals Supply Tender in Andalusia

Servicio Andaluz de Salud has hired Grifols for the supply of exclusive pharmaceuticals, intended for its Seville platform. The final value of the deal is EUR 198,000 (USD 222,000), VAT excluded. The contract term has not been specified.

Grifols, S.A. Announces Earnings Results for the Nine Months of 2014

Grifols, S.A. announced earnings results for the nine months of 2014. For the period, the company reported net revenue of EUR 2,438,090,000 against EUR 2,046,563,000 a year ago. Operating profit was EUR 631,221,000 against EUR 566,430,000 a year ago. Profit before tax was EUR 425,927,000 against EUR 385,639,000 a year ago. Consolidated profit for the period was EUR 336,482,000 against EUR 263,942,000 a year ago. EBITDA was EUR 769,756,000 against EUR 662,965,000 a year ago. Adjusted EBITDA was EUR 791,593,000 against EUR 690,367,000 a year ago. Net cash flow from operating activities was EUR 655,888,000 against EUR 365,707,000 a year ago. Free cash flow negative was EUR 779,891,000 against positive free cash flow of EUR 200,854,000 a year ago. CapEx was EUR 180,161,000 against EUR 100,131,000 a year ago.

Grifols, S.A. Approves Interim Dividend for the year 2014

Grifols, S.A. announced that in the meeting held on October 21, 2014, the Board of Directors approved payment of an interim dividend against 2014 profit of euro 0.25 per each share by which the company's share capital is represented. Payment of the interim dividend will be made the first week of December.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRF:SM €36.50 EUR -0.13

GRF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $79.73 USD +0.58
Hikma Pharmaceuticals PLC 2,350 GBp +35.00
Hospira Inc $65.49 USD -1.01
STADA Arzneimittel AG €27.37 EUR -0.233
UCB SA €70.01 EUR -0.43
View Industry Companies

Industry Analysis


Industry Average

Valuation GRF Industry Range
Price/Earnings 26.9x
Price/Sales 3.6x
Price/Book 4.4x
Price/Cash Flow 16.6x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at